Revvity, Inc. RVTY SPX
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 50.3.
- Revenue declined at -4.8% CAGR over 5 years.
- Earnings shrank at -24.9% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RVTY Revvity, Inc. SPX | 104.55 | 50.26 | $11.66B | 0.27% | 3.33% | 3.23% | -4.82% | -24.89% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Apr 2016 | Jul 2016 | Oct 2016 | Jan 2017 | Apr 2017 | Jul 2017 | Oct 2017 | Dec 2017 | Apr 2018 | Jul 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Apr 2020 | Jul 2020 | Oct 2020 | Jan 2021 | Apr 2021 | Jul 2021 | Oct 2021 | Jan 2022 | Apr 2022 | Jul 2022 | Oct 2022 | Jan 2023 | Apr 2023 | Jul 2023 | Oct 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 546.96M | 554.27M | - | 643.97M | 703.36M | 674.31M | - | 648.74M | 722.52M | 706.92M | - | 652.40M | 811.72M | 964.02M | - | 1.31B | 1.23B | 861.32M | - | 963.16M | 895.64M | 711.80M | - | 674.87M | 709.07M | 670.74M | 649.92M | 691.68M | - | 664.76M | 720.28M | 698.95M | 772.06M | 711.12M | 711.12M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 289.22M | 327.73M | 324.35M | 350.40M | 323.46M | - |
| Gross Profit | 235.09M | 253.55M | 248.55M | 276.16M | 239.76M | 257.60M | 268.97M | 307.43M | 292.22M | 340.14M | 332.33M | 376.25M | 307.81M | 347.79M | 342.27M | 398.18M | 308.02M | 447.34M | 527.45M | 827.07M | 693.19M | 574.14M | 522.86M | 643.80M | 594.74M | 551.72M | 407.04M | 436.33M | - | - | - | - | - | - | 375.55M | 392.56M | 374.60M | 421.66M | 387.65M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 303.32M | 303.49M | 292.71M | 309.91M | 311.77M | - |
| Operating Income | 60.58M | 66.27M | 75.78M | 80.44M | 49.81M | 74.18M | 78.04M | 93.58M | 39.94M | 88.06M | 80.20M | 115.68M | 53.33M | 91.73M | 78.66M | 138.25M | 44.68M | 175.64M | 248.01M | 510.25M | 455.01M | 308.00M | 195.55M | 299.89M | 261.96M | 232.49M | 110.78M | 137.47M | 76.12M | 78.06M | 69.23M | 44.12M | 85.72M | - | 72.23M | 89.06M | 81.90M | 111.75M | 75.89M | 75.89M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 172.77M | 194.37M | 180.52M | 218.15M | 179.77M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 22.96M | 22.94M | 22.77M | 23.51M | 24.72M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 52.38M | 68.65M | 55.69M | 91.56M | 49.99M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.71M | 13.43M | 8.46M | -4.21M | 9.10M | - |
| Net Income | 47.47M | 63.86M | 58.13M | 64.85M | 38.60M | 204.07M | 91.08M | -41.12M | 26.02M | 64.06M | 76.55M | 71.29M | 35.41M | 69.09M | 58.56M | 64.50M | 33.66M | 137.16M | 176.70M | 380.36M | 379.31M | 245.93M | 127.74M | 190.18M | 176.96M | 179.21M | 85.35M | 127.66M | 569.48M | 35.56M | 9.50M | 26.01M | 55.36M | - | 42.24M | 53.95M | 46.65M | 98.36M | 40.72M | 40.72M |
| Diluted EPS | 0.43 | 0.58 | 0.53 | 0.59 | 0.35 | 1.84 | 0.82 | -0.37 | 0.23 | 0.57 | 0.69 | 0.64 | 0.32 | 0.62 | 0.52 | 0.58 | 0.30 | 1.23 | 1.57 | 3.38 | 3.37 | 2.19 | 1.11 | 1.50 | 1.40 | 1.42 | 0.67 | 1.01 | 4.50 | 0.28 | 0.08 | 0.21 | 0.45 | - | 0.35 | 0.46 | 0.40 | 0.87 | 0.36 | 0.36 |
| R&D Expense | 29.97M | 31.87M | 29.51M | - | 33.29M | 33.56M | 34.88M | - | 45.98M | 47.20M | 48.85M | - | 47.98M | 48.34M | 45.38M | - | 48.91M | 49.52M | 50.13M | - | 60.22M | 65.82M | 49.42M | - | 57.52M | 56.04M | 53.52M | - | 56.69M | 57.25M | 53.04M | 50.36M | 48.13M | 49.14M | 53.60M | 53.27M | 50.80M | - | - | 57.89M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2008 | Jan 2010 | Jan 2011 | Jan 2012 | Dec 2012 | Dec 2013 | Dec 2014 | Jan 2016 | Jan 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Jan 2021 | Dec 2021 | Jan 2022 | Dec 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 2.12B | 2.26B | 2.78B | 2.88B | 2.66B | - | 3.83B | 3.31B | 3.31B | 2.75B | 2.76B | 2.86B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.32B | - | 1.21B | 1.22B | 1.29B |
| Gross Profit | - | - | 761.23M | 847.80M | 963.21M | 976.14M | 1.00B | 964.23M | 1.01B | 1.07B | 1.34B | 1.40B | 2.11B | - | 2.43B | 1.99B | 1.99B | 1.54B | 1.54B | 1.56B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.25B | - | 1.24B | 1.19B | 1.21B |
| Operating Income | 147.63M | 115.95M | 157.57M | 91.13M | 103.12M | 227.79M | 165.01M | 250.93M | 294.58M | 295.62M | 323.88M | 361.97M | 867.27M | - | 1.26B | 742.70M | 742.70M | 300.56M | 346.74M | 356.63M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.18B | - | 713.56M | 840.25M | 765.80M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 103.95M | - | 98.81M | 96.28M | 92.19M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 651.84M | - | 182.98M | 316.13M | 268.28M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 139.16M | - | 3.47M | 33.05M | 28.39M |
| Net Income | 126.41M | 82.08M | 390.98M | 7.66M | 69.94M | 167.21M | 157.78M | 212.43M | 234.30M | 292.63M | 237.93M | 227.56M | 727.89M | - | 943.16M | 569.18M | 569.18M | 693.09M | 270.38M | 241.20M |
| Diluted EPS | 1.07 | 0.70 | 3.31 | 0.07 | 0.61 | 1.47 | 1.39 | 1.87 | 2.12 | 2.64 | 2.13 | 2.04 | 6.49 | - | 8.08 | 4.58 | 4.50 | 5.55 | 2.20 | 2.07 |
| R&D Expense | 93.03M | 90.49M | 94.81M | 115.82M | 131.84M | 132.40M | 108.06M | 112.54M | 124.18M | 139.46M | 194.00M | 189.34M | 146.44M | - | 200.34M | - | 221.62M | 216.58M | 196.84M | 215.84M |
Compounded Sales Growth
| 5 Years: | -4.82% |
| 1 Year: | 7.00% |
Compounded Profit Growth
| 5 Years: | -24.89% |
| 1 Year: | 3.50% |
Stock Price Performance
| 1 Year: | +15.96% |
| 6 Months: | -0.83% |
| 3 Months: | +6.43% |
| 1 Month: | +27.10% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Jan 2010 | Jan 2011 | Jan 2012 | Dec 2012 | Dec 2013 | Dec 2014 | Jan 2016 | Jan 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Jan 2021 | Dec 2021 | Jan 2022 | Dec 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 3.06B | 3.21B | 3.86B | 3.90B | 3.95B | 4.13B | 4.17B | 4.28B | 6.09B | 5.98B | 6.54B | 7.96B | - | 15.00B | 14.13B | 14.13B | 13.56B | 12.39B | 12.17B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.29B | - | 3.00B | 2.35B | 2.24B |
| Cash & Equivalents | 203.35M | 179.11M | 179.71M | 420.09M | 142.34M | 173.24M | 174.82M | 174.82M | 237.93M | 359.26M | 202.13M | 163.11M | 191.88M | 387.05M | - | 603.32M | 454.36M | 454.36M | 913.16M | 1.16B | 919.86M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 405.46M | - | 428.06M | 367.59M | 379.50M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 612.78M | - | 632.81M | 632.40M | 744.67M |
| Total Liabilities | - | - | 1.43B | 1.28B | 2.01B | 1.96B | 1.95B | 2.09B | 2.06B | 2.12B | 3.59B | 3.39B | 3.72B | 4.22B | - | 7.86B | 6.75B | 6.75B | 5.69B | 4.73B | 4.92B |
| Current Liabilities | - | - | 497.20M | 515.20M | 598.68M | 581.10M | 602.80M | 597.31M | 561.49M | 603.36M | 950.90M | 771.63M | 762.83M | 1.65B | - | 1.21B | 1.54B | 1.54B | 1.45B | 653.10M | 1.33B |
| Long Term Debt | - | - | 558.20M | 424.00M | 944.91M | 938.82M | 932.10M | 1.05B | 1.01B | 1.05B | 1.79B | 1.88B | 2.06B | 1.61B | - | 4.98B | 3.92B | 3.92B | 3.18B | 3.15B | 2.63B |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.60B | - | 4.07B | 3.33B | 3.40B |
| Total Equity | 1.58B | 1.57B | 1.63B | 1.93B | 1.84B | 1.94B | 1.99B | 2.04B | 2.11B | 2.15B | 2.50B | 2.58B | 2.81B | 3.74B | - | 7.14B | 7.38B | 7.38B | 7.87B | 7.67B | 7.25B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 126.30M | - | 123.43M | 120.65M | 112.28M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2008 | Jan 2010 | Jan 2011 | Jan 2012 | Dec 2012 | Dec 2013 | Dec 2014 | Jan 2016 | Jan 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Jan 2021 | Dec 2021 | Jan 2022 | Dec 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 217.84M | 148.72M | 164.25M | 224.87M | 152.17M | 158.59M | 281.60M | 287.10M | 350.62M | 288.45M | 311.04M | 363.47M | 892.18M | - | 1.41B | 679.81M | 679.81M | 91.27M | 628.30M | 582.93M |
| Investing Cash Flow | -135.68M | -153.87M | 295.15M | -909.86M | -80.31M | -1.21M | -295.90M | -100.86M | -83.88M | -1.27B | -159.86M | -487.57M | -504.50M | - | -4.11B | -132.85M | -132.85M | 1.31B | 776.16M | -17.35M |
| Financing Cash Flow | -101.08M | 2.41M | -218.37M | 397.20M | -44.16M | -154.16M | 30.93M | -107.14M | -115.01M | 782.24M | -179.23M | -150.13M | -202.87M | - | 2.94B | -661.80M | -661.80M | -947.12M | -1.13B | -857.52M |
| Capital Expenditure | -35.27M | -25.52M | -33.65M | -30.59M | -42.40M | -38.98M | -27.15M | -28.22M | -31.70M | -39.09M | -93.25M | -76.33M | -63.63M | - | -86.02M | -85.63M | -85.63M | -81.37M | -86.65M | -73.52M |
| Free Cash Flow | 182.57M | 123.21M | 130.61M | 194.28M | 109.77M | 119.61M | 254.44M | 258.88M | 318.91M | 249.36M | 217.78M | 287.14M | 828.54M | - | 1.32B | 594.18M | 594.18M | 9.90M | 541.65M | 509.41M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -114.84M | - | 457.68M | 276.23M | -291.94M |
| Share Buybacks | 75.51M | 14.62M | 72.77M | 110.00M | 2.10M | 127.40M | 65.53M | 76.44M | 151.80M | 3.83M | 57.45M | 6.31M | 6.94M | - | 73.07M | - | 80.64M | 388.88M | 369.58M | 820.82M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2008 | Jan 2010 | Jan 2011 | Jan 2012 | Dec 2012 | Dec 2013 | Dec 2014 | Jan 2016 | Jan 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Jan 2021 | Dec 2021 | Jan 2022 | Dec 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | 47.9% | 47.6% | 48.3% | 48.4% | 79.2% | - | 63.6% | 60.1% | 60.1% | 56.0% | 55.8% | 54.8% |
| Operating Margin % | - | - | - | - | - | - | - | - | 13.9% | 13.1% | 11.7% | 12.6% | 32.6% | - | 32.9% | 22.4% | 22.4% | 10.9% | 12.6% | 12.5% |
| Net Margin % | - | - | - | - | - | - | - | - | 11.1% | 13.0% | 8.6% | 7.9% | 27.3% | - | 24.6% | 17.2% | 17.2% | 25.2% | 9.8% | 8.4% |
| ROE % | 8.1% | 5.0% | 20.3% | 0.4% | 3.6% | 8.4% | 7.7% | 10.1% | 10.9% | 11.7% | 9.2% | 8.1% | 19.5% | - | 13.2% | 7.7% | 7.7% | 8.8% | 3.5% | 3.3% |
| ROCE % | - | 4.5% | 5.8% | 2.8% | 3.1% | 6.8% | 4.7% | 7.0% | 8.0% | 5.8% | 6.2% | 6.3% | 13.7% | - | 9.1% | 5.9% | 5.9% | 2.5% | 3.0% | 3.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | T. Rowe Price Investment Management, Inc. | 19.90% | 22.20M | $2.32B |
| 2 | Price (T.Rowe) Associates Inc | 9.04% | 10.09M | $1.05B |
| 3 | Edgepoint Investment Group Inc. | 7.89% | 8.80M | $920.13M |
| 4 | Janus Henderson Group PLC | 7.48% | 8.35M | $872.80M |
| 5 | Vanguard Capital Management LLC | 6.57% | 7.33M | $766.35M |
| 6 | Blackrock Inc. | 6.50% | 7.25M | $758.03M |
| 7 | Vanguard Portfolio Management LLC | 4.31% | 4.81M | $503.22M |
| 8 | State Street Corporation | 3.86% | 4.31M | $450.64M |
| 9 | Victory Capital Management Inc. | 3.02% | 3.37M | $352.61M |
| 10 | Geode Capital Management, LLC | 2.63% | 2.94M | $307.08M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RVTY